Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Agilent Supports Russell Thomas’ Research at the Hamner Institutes for Health Sciences

Published: Thursday, December 08, 2011
Last Updated: Thursday, December 08, 2011
Bookmark and Share
Russell supported for his work developing methods to predict drug-induced liver injury.

Agilent Technologies Inc. and the Agilent Technologies Foundation have announced that Russell S. Thomas, Ph.D., of the Hamner Institutes for Health Sciences has been selected for an Agilent Thought Leader Award to support his work developing methods to predict drug-induced liver injury.

The award includes funding from the Agilent Technologies Foundation as well as instrumentation from the company, including a 6460 triple quadrupole LC/MS and an Agilent microarray scanner.

Dr. Thomas is director of the Institute for Chemical Safety Sciences at the Hamner, where researchers are applying a systems biology approach in an effort to predict drug-induced liver injury.

This includes integration of data from transcriptomics, metabolomics, and genome-wide association studies.

Drug-induced liver injury is a primary reason regulators prohibit drugs or pull them off the market. One of the goals of Dr. Thomas’ work is to eventually be able to identify patients with genetic susceptibility to liver damage from certain drugs. This could reduce injuries and even allow some previously banned drugs to be reintroduced.

“Drug-induced liver injury is a major problem in the development of safe and effective therapeutics,” said Dr. Thomas.

Dr. Thomas continued, “Current analyses of the genome sequence data of patients that have experienced drug-induced liver injury have failed to identify any susceptibility factors that are common across multiple drugs. I am grateful to receive the Agilent Thought Leader Award as an acknowledgment of the importance of the work we are conducting at the Hamner Institutes. The award will allow us to evaluate whether these susceptibility factors can be identified when the drugs are grouped based on the signaling pathways they activate in the liver and ultimately predict which patients may be at risk.”

“The promise of personalized medicine is getting closer every day, and this is why we appreciate the opportunity to help make a real difference by supporting work like Dr. Thomas’,” said Gustavo Salem, vice president and general manager of Agilent’s Biological Systems Division.

Salem continued, “We’ve been strong proponents of an integrated biology approach to solving important health problems for quite some time, and this research at the Hamner aligns well with Agilent’s goals.”

The Agilent Thought Leader Program promotes fundamental advances in the life sciences by contributing financial support, products and expertise to the research of thought leaders.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Completes Acquisition of Seahorse Bioscience
Agilent has completed the acquisition of Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics.
Tuesday, November 03, 2015
Agilent Announces Opening of Life Science Research Center
Facility designed to advance multi-omics research.
Thursday, September 24, 2015
Agilent to Acquire Seahorse Bioscience
Acquisition complements Agilent’s market-leading separations and mass spectrometry solutions, expands pharma offerings.
Thursday, September 10, 2015
Agilent to Focus on "Powerful Partnerships, Inspiring Results" at ASMS 2015
Company to introduce solutions enabling new standards in mass spectrometry, lab productivity.
Friday, May 29, 2015
Agilent, Baylor Open Mass Spec Center of Excellence
The new facility aims to boost metabolomics research at Baylor College of Medicine.
Friday, December 05, 2014
Agilent Thought Leader Award Supports Metabolic Research
Princeton team developing LC/MS methods, bioinformatics tools for discovery of metabolic regulatory mechanisms.
Tuesday, April 22, 2014
Agilent to Host Young Scientist Forums in Asia Pacific
Events provide platform for rising talents in Australia, Singapore to exchange ideas with leading scientific scholars.
Wednesday, March 26, 2014
Agilent, CambTEK Announce LC Sample Prep Agreement
Companies announce agreement to co-market CambTEK's RES automated sample preparation technology with an assortment of Agilent's instruments and software.
Wednesday, February 26, 2014
Agilent Awards Grant for Translational Research in Cardiometabolic Disease
Dr. Christopher Newgard's team at Duke University use Agilent platforms to better understand disease mechanisms.
Thursday, January 16, 2014
Agilent Thought Leader Award Supports Dr. Junying Yuan, Chinese Academy of Sciences
Integrated biological research is accelerating drug development for neurodegenerative diseases.
Wednesday, December 11, 2013
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent Recognized as 2013 Laboratory Analytical Instrumentation Company of the Year in China
The company ranked highest in industry for leadership, growth, innovation and customer service by Frost & Sullivan.
Tuesday, August 20, 2013
Agilent and SRI International Sign Licensing Agreement
Agilents’ new pathway Architect software to include SRI International’s BioCyc Pathway database collection.
Wednesday, April 17, 2013
Agilent and Spain’s Centre for Omic Sciences to Collaborate
Both Companies collaborate on integrated systems biology research, establish centre of excellence.
Tuesday, March 05, 2013
Agilent Technologies Thought Leader Award Supports Translational Research Program
The award will support Dr DePinho's research into metabolic reprogramming in the earliest stages of cancer.
Monday, March 04, 2013
Scientific News
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.
Cellular Stress Process Identified in Cardiovascular Disease
Combining the investigative tools of genetics, transcriptomics, epigenetics and metabolomics, a Duke Medicine research team has identified a new molecular pathway involved in heart attacks and death from heart disease.
Predicting Adverse Drug Reactions with Higher Confidence
A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods.
A New Way to Starve Lung Cancer?
Metabolic alterations in lung cancer may open new avenues for treating the disease.
Evidence of How Incurable Cancer Develops
Researchers in the West Midlands have made a breakthrough in explaining how an incurable type of blood cancer develops from an often symptomless prior blood disorder.
Building a Better Liposome
Computational models suggest new design for nanoparticles used in targeted drug delivery.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos